📷 Image: Wikimedia Commons / Original: Harshit SR
Derivative work: Unpetitpro
Health
CDSCO Orders Halt to Uttarakhand Pharma Unit Over GMP Violations
✍️ Medical Dialogues
🗓 08 Nov 2026, 11:32 AM
👁 15
The Central Drugs Standard Control Organization (CDSCO) has flagged serious Good Manufacturing Practice (GMP) concerns at a pharmaceutical unit in Uttarakhand and has ordered an immediate halt to its production.
The Central Drugs Standard Control Organization (CDSCO) has identified significant Good Manufacturing Practice (GMP) deficiencies at a pharmaceutical manufacturing unit located in Uttarakhand.
Following the inspection, CDSCO has issued a directive to stop all production activities at the facility immediately.
The unit, which produces pharmaceutical products, is now under regulatory scrutiny to address the identified GMP lapses before any resumption of manufacturing.
The halt may temporarily impact the supply of the unit’s products, and CDSCO will likely conduct further inspections to ensure compliance with national drug standards.
Following the inspection, CDSCO has issued a directive to stop all production activities at the facility immediately.
The unit, which produces pharmaceutical products, is now under regulatory scrutiny to address the identified GMP lapses before any resumption of manufacturing.
The halt may temporarily impact the supply of the unit’s products, and CDSCO will likely conduct further inspections to ensure compliance with national drug standards.